Digest Network Come funziona
Network
/
Società
In
Non verificato

Inflammasome Therapeutics

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieSaluteScienza

7 comunicati stampa

Guarda tutti i comunicati
07/10/2026
Eventi
Fiere
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Ottica
Inflammasome Therapeutics to Present New Phase 2 Analyses of K8 in Geographic Atrophy at AAO Retina Subspecialty Day
Fonte
Inflammasome Therapeutics
Emittente
Business Wire
1.00
0
17/07/2026
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Ottica
Industria
Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy
Fonte
Inflammasome Therapeutics
Emittente
Business Wire
1.00
0
25/11/2025
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy
Fonte
Inflammasome Therapeutics
Emittente
Business Wire
1.00
0
13/11/2025
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Mercato del lavoro
Industria
Inflammasome Therapeutics to Collaborate with Sean M. Healey & AMG Center for ALS on a new treatment for Amyotrophic Lateral Sclerosis (ALS)
Fonte
Inflammasome Therapeutics
Emittente
Business Wire
1.00
0
11/09/2025
Scienza
Salute
Medicina - Varie
Biotecnologia
Sanità
Ottica
Industria
Inflammasome Therapeutics’ K8 Implant Cuts Lesion Growth by more than 50% in Geographic Atrophy after Three Months in Multi-Center Trial
Fonte
Inflammasome Therapeutics
Emittente
Business Wire
1.00
0
15/01/2025
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Ottica
Inflammasome Therapeutics Announces Topline 3-month Data from a Clinical Trial of its First-in-Class Dual Inflammasome Inhibitor, K8, in Geographic Atrophy, Demonstrating Rapid, Substantial and Significant Efficacy and Safety
Fonte
Inflammasome Therapeutics
Emittente
Business Wire
1.00
0
10/09/2024
Industria
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
Medicina - Varie
Inflammasome Therapeutics Completes Enrollment in Study for First Oral Dual Inflammasome Inhibitor for Ophthalmic and Neuroinflammatory Diseases
Fonte
Inflammasome Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0